Table 2a.
Number of clinical indications for the marketed antibody-based biotherapeutics*.
| Marketed Biotherapeutic | Number of Clinical Indications served |
|---|---|
| Pembrolizumab | 18 |
| Nivolumab | 12 |
| Adalimumab | 9 |
| Infliximab | 8 |
| Bevacizumab | 7 |
| Ipilimumab | 7 |
| Tocilizumab | 7 |
| Canakinumab | 6 |
| Certolizumab pegol | 6 |
| Rituximab | 6 |
| Ustekinumab | 6 |
| Atezolizumab | 5 |
| Dupilumab | 5 |
| Golimumab | 5 |
| Ranibizumab | 5 |
| Secukinumab | 5 |
| Brentuximab vedotin | 4 |
| Durvalumab | 4 |
| Eculizumab | 4 |
| Ixekizumab | 4 |
| Mepolizumab | 4 |
| Ramucirumab | 4 |
*This table shows the 89 marketed antibody-based biotherapeutic and how many clinical indications for which it has been approved as of December 2022. For example, pembrolizumab has been approved for most clinical indications, 18 so far. Only antibody-based biotherapeutic products approved for four or more clinical indications were included in this table. Please refer to Table S1 for full details.